Detalhe da pesquisa
1.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood
; 131(14): 1522-1531, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29358182
2.
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Ann Hematol
; 99(10): 2215-2229, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32856140
3.
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Blood
; 127(11): 1410-6, 2016 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-26755709
4.
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.
Haematologica
; 101(12): 1524-1533, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27587380
5.
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
Cancer Discov
; 14(1): 90-103, 2024 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861452
6.
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Cancer Discov
; 14(1): 76-89, 2024 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37861461
7.
STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer.
Cancers (Basel)
; 14(16)2022 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36011027
8.
Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.
Hematology
; 24(1): 337-348, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30757960
9.
Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Expert Opin Biol Ther
; 15(8): 1093-9, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25971805
10.
Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.
Cancer Res
; 68(2): 597-604, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18199557
11.
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
J Immunother
; 31(9): 871-84, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18833000
12.
Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.
Cancer Immunol Immunother
; 57(2): 233-46, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17665197
13.
Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.
J Immunother
; 29(2): 122-33, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16531813